A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
TG Therapeutics, Inc
Start Date
September 1, 2016
End Date
August 31, 2022
Administered By
Duke Cancer Institute
Awarded By
TG Therapeutics, Inc
Start Date
September 1, 2016
End Date
August 31, 2022